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ABSTRACT 
 
Angiogenesis  is  the  formation  of  new  capillaries  from  pre-existing  capillaries.  Angiogenesis 
plays an important role in the blood vessel formation required during embryonic development, 
tissue injury, wound healing, and menstruation. It also plays a major role in tumor progression. 
We  propose  a  mechanism  that  links  the  developmental  pathways  to  a  therapeutic  pathway. 
Moreover, we show anti-angiogenic nature of an FDA approved immunosuppressant.  
Extra cellular matrix (ECM) has an important role in maintaining the shape and structure of 
organisms  and  in  signaling  mechanisms.    Two  major  components  of  ECM  are  lumican  and 
Magp2. Investigating their role might help us further link angiogenesis to tumor progression in 
cancer.  We show the pro-angiogenic nature of Magp2 in an in-vivo model. Although this project 
is in early stages, it would provide a good foundation for future study. 
The aim of this thesis was to check the effect of blocking angiogenesis on tumor growth through 
different ECM proteins (Lumican and Magp2) and therapeutics (cyclosporine-A). Studying the 
progression of tumor links the chapters together.  
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PREFACE 
The  aim  of  this  thesis  is  to  demonstrate  the  importance  of  angiogenesis  during  cancer 
progression. This thesis consists of three chapters that aim to improve the understanding of an 
already  approved  immunosuppressant,  Cyclosporine-A,  on  angiogenesis  and  the  effects  of 
extracellular matrix proteins on cancer progression, thus increasing the understanding of the role 
of angiogenesis in cancer progression. 
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CHAPTER 1 
PROLOGUE 
Since first mentioned by Hippocrates around 400 BC as karkinos (Greek for Crab), the 
knowledge about cancer has increased tremendously. From once believed to be the black fluid in 
the patient, cancer has come long ways to be treated, if not cured[1]. Evidence shows that the 
first  mastectomy  was  performed  as  early  as  the  sixteenth  century,  while  people  were  still 
discovering cancer as a disease [1]. Fast forward several centuries, hundreds of mastectomies are 
performed every day and the survival rate has increased tremendously. These advancements in 
the treatment (or at least better understanding) of cancer are due to great research taking place 
around the world in this field. Here, we try to provide a link between mechanisms that are 
involved in normal vascular development and cancer progression and attempt to enhance the 
understanding of this mysterious disease.   
Cancer is a very complex disease with each form of cancer distinctively different from 
the others but carrying some common features, which make them ‘cancer’[1]. The complexity of 
this disease can be estimated by the extensive efforts by the government to eradicate, or at least 
restrict, the metastasis of cancer. But over time more and more cases are seen. This may be due 
to  the  better  screening  and  diagnosis  of  the  disease  but  the  adverse  effects  of  increasing 
carcinogens in our surroundings cannot be discarded. According to the National Cancer Institute 
of United States, 541 men and 411 women, per 100,000 would be diagnosed with cancer in five 2 
 
years. Taken the same rate of ~.5%, 1.5 million Americans would be affected. The severity of 
this disease can only be appreciated by  citing the five  year death  rate  of cancer which is  a 
staggering 223 men and 153 women, per 100,000, for a period of five years. The current trends 
are synchronic with these statistics. One in every two men and women will develop some type of 
cancer in their life time, rates of which get higher with age [2], but there is good news. It is 
reported that mortality  rate due to cancer is on a decline; a per  annum decrease of ~2% in 
mortality rate was seen between 2002 and 2004, whereas this was only ~1% from 1993 to 2002. 
Moreover, there are over 10 million people in the United States that have survived cancer and are 
living [3]. Despite these successes current efforts are not adequate to deal with this extensive 
array of diseases that are summed up as cancer. There are groups studying cancer worldwide and 
in US, but the rate of governmental support in funding has not been able to keep up with the 
diagnosis rate. There has been a steady rate of funding towards the cancer research since 2004 
and adjusted for inflation, research budget decreases by over 10% [3]. In conclusion, there is a 
tremendous need to scale up the research for our ‘fight against cancer’.  
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MANIPULATION OF ANGIOGENESIS BY CYCLOSPORINE-A AND EXTRACELLULAR 
MATRIX MOLECULES 
 
Hallmarks of Cancer 
   Hanahan, et. al., in ‘Hallmarks of Cancer’ a review in 2000,  discussed six hallmarks of 
cancer [4]. These hallmarks are always present in a cancer, and each aspect is being studied in 
immense  detail.  These  hallmarks  range  from  abnormalities  in  apoptosis,  insensitivity  to 
antigrowth  signals,  unlimited  replicating  potential,  excessive  angiogenesis,  proliferation,  and 
spreading to other parts of the body or metastasis [4, 5]. This list grew to ten in over a decade 
when reported in ‘Hallmarks of Cancer: Next generation’. Four new additions, which include 
triggering genetic mutations, resistance to host immune response, excessive inflammation, and 
disruption of cellular integrity were added [5]. A mutated cell requires all these hallmarks to 
become cancerous and metastasize to other parts of the body. In theory inhibiting one of these 
hallmarks can be enough to prevent the progression and spread of cancer. Here we discuss the 
ideas of inhibiting one of the hallmarks of cancer, angiogenesis, and preventing the progression 
of tumor.  
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Angiogenesis 
The term ‘Angiogenesis’ was first mentioned, in 1787, by an English Physician Dr. J. 
Hunter [6]. Almost two centuries later, the American physician Dr. J. Folkman elaborated this 
term and put forth several research findings showing the relationship of tumor development to 
angiogenesis [7-9].  
Angiogenesis is defined as the development of new blood vessels from existing vessels 
and is an important phenomenon required during wound healing, reproduction, and menstruation 
[10]. Healthy cells require oxygen and nutrients in order to keep up their continuous dividing 
potential, and this is achieved by maintaining a distance approximately 200µm  or less, from a 
blood vessel [10]. When this distance is beyond 200µm, it is either time for the cell to die 
(through apoptosis) or a new blood vessel to develop (during embryonic development) which 
restores the supply of nutrients. To continue the supply of nutrients to cells that are not only 
impervious to death but also dividing at a very rapid rate, the development of new blood vessels 
is escalated in the body and termed angiogenesis. The tissue in need of blood vessels (be it from 
injury or due to presence of tumor) secretes growth factors. These growth factors signal the 
blood vessels in the vicinity to facilitate the steps required to grow new cells towards the tumor 
(or injury site).  These signals from the tumor cause the endothelial cells of the blood vessels to 
begin proliferating and migrating towards tumors. These cells remodel, invade the tissue in the 
path to the tumor, and develop a bridge like layer of cells connecting the preexisting blood vessel 
to the tumor. At this time the loop formation is completed and these newly formed blood vessels 
attain vascular stability with the help of adhering molecules in the micro-environment [11, 12].  5 
 
Again, angiogenesis is the development of new blood vessels to the tumors for nutrient 
supply and this is a very complex phenomenon. Since the discovery of angiogenesis almost four 
decades ago the understanding of its complex role in the body has increased tremendously. Since 
first discussed in 1971, the importance of angiogenesis during tumor development has been well 
established [7, 13], but it is not only prevalent during tumor growth, angiogenesis is required 
during normal development of blood vessels too. During embryonic development a vast array of 
blood vessels develop in the body. The rate of development decreases with age, and is limited to 
wound healing, tissue repair, and menstruation in adults [14, 15].  
   The rate of angiogenesis slows down in adults, and a balanced angiogenesis is essential. 
Balanced angiogenesis helps during wound healing, but a disruption in this balance can lead to 
many  disorders  such  as  asthma,  Alzheimer’s,  arthritis,  and  psoriasis  [10,  16].  A  balance  in 
angiogenesis is maintained by pro and anti angiogenic molecules present in the body. Moreover, 
it is an imbalance in these molecules that stimulates or suppresses angiogenesis. There is an ever-
growing  list  of  these  molecules.  Pro-angiogenic  molecules  like  vascular  endothelial  growth 
factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), 
and platelet factor 4 (PF4) are found at increased levels in some cases of cancer [9, 17]. Along 
with these molecules controlling the development of blood vessels, there are critical steps during 
the process of angiogenesis that have to occur in synchrony for this growth to occur. These steps 
are shown in figure 1. For instance, steps like secretion of pro-angiogenic molecules by the 
tumor  are  especially  critical  to  trigger  the  endothelial  cell  proliferation  from  the  preexisting 
vessel .In the ever-growing list of pro and anti angiogenic molecules, VEGF is one of the pro-
angiogenic that has been most widely studied and understood [10]. Evidence of this is the only 
FDA approved anti-angiogenic drug that blocks VEGF, Avastin [18, 19].  6 
 
Pro-angiogenic molecules cause excessive development but again the balance can also be 
disrupted by anti-angiogenic molecules and insufficient angiogenesis can also lead to a variety of 
diseases  in  a  body.  Insufficient  angiogenesis  can  lead  to  slower  wound  healing,  excessive 
bleeding, stroke, and many other diseases associated with development [10, 16]. In conclusion it 
is  this  balance  of  pro-  and  anti-angiogenic  molecules  that  is  required  for  a  healthy  life.  In 
addition to the pro and anti-angiogenic molecules, tumor microenvironment has also been shown 
to impact the development of tumor. 
The tumor microenvironment, in addition to structural molecules such as collagens, also 
contains  matricellular  molecules  or  proteins.  These  matricellular  proteins  are  known  to 
manipulate cell surface receptors [20]. These cell surface receptors play a major role in intrinsic 
cellular  pathways  leading  to  tumorigenesis  and  angiogenesis  [21].  Two  such  matricellular 
proteins  shown  to  be  important  regulators  of  angiogenesis  are  Lumican  and  Microfibril-
associated glycoprotein-2 (Magp2). Lumican is well known for its structural role as a collagen 
organizing  molecule  in  the  microenvironment.  However,  elevated  lumican  levels  have  been 
reported  in  many  cancer  types,  namely  melanoma,  breast,  pancreatic,  colorectal,  cervical, 
neuroendocrine, and lung [22-27]. Lumican is also reported to retard the growth of subcutaneous 
mouse tumors [28, 29]. It was also reported to reverse the effect of pro-angiogenic molecule, 
bFGF, thus proving its role as an endogenous anti-angiogenic molecule [30] and defining its role 
as a matricellular protein. Magp2 is known for its structural role as a component of the elastic 
fiber protein [31]. As a matricellular protein Magp2 has been associated with endothelial cells 
differentiation  fate  and  tumor  cell  progression  [32].  Moreover,  its  role  in  regulating  notch 
signaling  pathway  has  also  been  reported  [33].  Notch  pathway  is  known  to  be  involved  in 
developmental stages and play a crucial role in angiogenesis.  7 
 
Notch Signaling Pathway  
Cellular co-operation requires a mechanism enabling cell communication. One way this 
is achieved is by direct cell-cell interactions. Cell-Cell interactions take place with the help of 
ligands on the cell surface. Notch is a signaling pathway during development, when cells interact 
to transmit signals. Development of tissues and organ systems in the body requires a functioning 
and balanced notch signaling. Notch controls  many developmental aspects [34]. Notch signals 
are triggered as a result of cell-cell interaction between the notch receptors on receiving cells and 
delta and serrate also known as DSL ligands from the signal sending cell; shown in figure 2[34]. 
Four notch receptors (notch1 – notch4) are known in mammals along with five DSL ligands that 
bind to and activate notch receptors (jagged 1, jagged2, delta-like 1(Dll1), Dll3, and Dll4). It is 
the contact of these receptors and ligands that causes the cleavage of notch into the intracellular 
domain of notch (NICD). This NICD requires a three step cleavage of notch, the first of which is 
facilitated  by  metalloprotease  tumor  necrosis  factor-α-converting  enzyme  (TACE).  A  second 
cleavage is a result of a multiple protein association, namely presenilins, nicastrin, APH1, and 
PEN2; the third cleavage involves an active role by gamma-secretase [35]. This third and final 
cleavage  allows  the  transport  of  NICD  into  the  nucleus,  where  it  activates  the  transcription 
factors, suppressor of hairless and RBP-J [34]. Notch signaling is essential for development of 
many tissue types in the body. For instance its  roles in sensory hair cell differentiation in the 
inner ear [36], somitogenesis [37], and cardiac  development [38, 39] have been shown, and 
further research in its role in central nervous system development is being conducted [34]. In 
conclusion significance of notch’s role in development is well-established.  
Notch is not only important during embryogenesis but is also crucial during angiogenesis. 
During vascular development, endothelial cells migrate and proliferate towards the tumor. In fact 8 
 
tip  cells  lead  the  migration  while  stalk  cells  facilitate  proliferation.  This  migration  and 
proliferation is maintained by a balanced Jagged1 and Delta4 activity. Jagged1 present on tip 
cells is known to drive tip cell formation, whereas dll4 present on tip cells drives the stalk cell 
formation  and  acts  as  a  feedback  inhibitor  of  excessive  dll4.  [40].  An  activation  of  notch 
signaling ligand dll4 was reported with increased VEGF levels (pro-angiogenic molecule) [41] 
indicating a close relation of notch signaling in controlling angiogenesis.  
Anti-angiogenesis  
Angiogenesis is one of the hallmarks of cancer and has been hypothesized to be a key 
regulator of tumor size. If the tumor size can be kept constant, metastasis could be prevented, 
and the tumor can be surgically removed. The new connections of tumor to the blood circulation 
not only provides the nutrient but also helps the tumor metastasize to other parts of the body[42]. 
Reportedly there are over two dozen anti-angiogenic drugs currently in development or clinic 
trials [43]. The cost of discovering  and developing a new drug from ‘bench to bedside’ has been 
estimated at a staggering $800 million over a decade of time [44].  Most of these anti-angiogenic 
drugs seek to neutralize one or more of the pro-angiogenic molecules, such as VEGF. However, 
this anti-angiogenic approach has not yet been successful.  
Cyclosporine-A as an anti-angiogenic 
Given the cost and time involved in developing, testing, and marketing of new drugs [44] 
discovering and exploiting new activities for FDA approved drugs is a cost-effective alternative 
to  drug  development.  One  such  drug,  cyclosporine-A  (CsA),  is  clinically  used  as  an 
immunosuppressant;  however  it  has  also  been  shown  to  block  angiogenesis.  As  an 
immunosuppressant  CsA  prevents  the  rejection  of  a  transplanted  organ  by  the  recipient’s 9 
 
immune  response  during  organ  transplant.  The  usage  of  immunosuppressants,    pre  and  post 
organ  transplant,    has  been  linked  to  complications  arising  due  to  a  chronically  suppressed 
immune response [45]. Skin lesions and development of lymphoma, along with metastasis to 
different part of the body, are noticed in many patients on an immunosuppressant post organ 
transplant [46]. Moreover, there are studies that link one type of immunosuppressant, namely the 
calcineurin inhibitors, to a higher rate of cancer proliferation [46]. Therefore, its use as an anti-
angiogenic is still under research. However, research has shown CsA to be a tumor suppressor in 
mouse models  [47]. A literature review of CsA shows both positive and negative effects and 
there is not one side establishing its efficiency as a better drug. Cyclosporine-A (CsA) was first 
discovered from a soil bacterium Tolypocladium inflatum by Borel in 1976 [48]. As depicted in 
figure 3, CsA is known to bind to cyclophilin (CpN) forming a dimer which inhibits calcineurin 
activity  [49].  Calcineurin  normally  dephosphorylates  the  Nuclear  Factor  of Activating T-cell 
(NF-AT)  which  is  critical  for  transcription  of  the  IL-2  gene.  By  preventing  the  IL-2,  CsA 
prevents T-cell activation and thus suppresses immune function. [48, 50]. 
In  addition to its role as an immunosuppressant, CsA was also shown to be an anti-
angiogenic [51, 52] that functions by blocking VEGF [53]. VEGF increases the proliferation of 
endothelial cells that results in excessive angiogenesis [18, 54, 55] by activation of NF-AT [56]. 
This NF-AT is the target of calcineurin, which is inhibited by CsA. Therefore CsA blocks this 
action of VEGF by preventing the dephosphorylation of NF-AT [57]. For this reason we attempt 
to explore the known mechanisms of CsA and link them back in a different and novel way of 
suppressing angiogenesis. 
As mentioned above, CsA has been shown to block angiogenesis is various models such 
as mouse models and in-vitro models. However, recently a new model of angiogenesis study has 10 
 
been  developed,  Danio  rerio,  Zebrafish.  For  example  the  transparent  body  and  visible 
vasculature is very advantageous when studying angiogenesis.   
Zebrafish Model 
Similarity of the genome and organ development with the mammalian system and over 
80% of its genome being sequenced makes zebrafish a very analogous model to mammalian 
[58]. Moreover, developmental processes like angiogenesis are similar between these fish and 
humans. Being a translucent species, zebrafish has been an excellent model for the study of 
vasculogenesis  and  angiogenesis.  Defects  in  intersegmental  vessels  (ISV)  due  to  blocked 
angiogenesis can be seen distinctively under a fluorescence microscope. Transgenic zebrafish 
Tg(fli1:eGFP/gata1:RFP) expressing green fluorescent protein (GFP) in endothelial cells and red 
fluorescent  protein  (RFP)  in  blood  cells  were  donated  by  Stephen  C.  Ekker(Mayo  Clinic, 
Rochester MN). Green fluorescent protein (GFP) gene is inserted downstream of an endothelial 
cell specific fli1 promoter, whereas red fluorescent protein (RFP) is inserted downstream of an 
erythroid  transcription,  gata1  promoter.  GFP  is  expressed  all  over  endothelial  cells,  whereas 
gata1 is expressed in the erythroid and all other blood cells [59].  
These fish, when fully developed, have their blood vessels glow green (due to GFP) and 
blood in the system glow red (due to RFP). These fish, when grown in the presence of CsA, have 
an abnormal angiogenesis which is further investigated in chapter 2.  
Summary 
Since  the  discovery  of  the  role  of  angiogenesis  in  tumor  progression  and  cancer 
proliferation,  angiogenesis  research  has  made  some  progress  in  inhibiting  angiogenesis  and 
preventing tumor growth. Avastin, an FDA approved drug, is known to block VEGF, and thus 11 
 
prevent  angiogenesis.  Moreover,  it  is  not  just  pro-angiogenic  molecules  like  VEGF  that  are 
important for tumor growth, but the microenvironment is also known to regulate angiogenesis.  
In this thesis we investigate the effects of a therapeutic CsA on angiogenesis.  We study 
specific mechanisms that are involved in angiogenesis and can inhibit angiogenesis. We also 
look  at  different  mechanisms  cross-talking  and  regulating  angiogenesis,  to  provide  some 
information about the cascade of events that lead to cancer development and progression.  
Developmental notch signaling is explored further in chapter 2. Since notch signaling 
requires ligand binding from the adjacent cells [34] blocking dll4 has been seen to promote tip 
cell formation and control sprouting of vessels while Jagged1 has been known to reverse this 
excessive tip cell formation [60]. We have proposed a mechanism in figure 4 that drives this 
balance of dll4 and jagged1. In this thesis we plan to increase our understanding of dll4/jagged1 
balance by known inhibitors. While some show importance of cyclophilin and not calcineurin in 
angiogenesis [52], some show the contrary [49]. Blocked angiogenesis is linked to blocked notch 
pathway [49]. We further investigate this cross talking phenomenon.  
In addition to pro and anti-angiogenic molecules that control angiogenesis, matricellular 
protein also plays a crucial role in angiogenesis. Two such proteins, Lumican and Magp2, are 
explored for their role in cancer progression and tumor angiogenesis. While lumican is tested for 
its effects on cancer progression, Magp2 is studied for its pro-angiogenic nature.  
Cancer will affect over a million people in the United States and is one of the most deadly 
diseases of our time. Over the time and along with novel research in the field, the survival rate 
has been improving. From Dr. Folkman’s angiogenesis theory to anti-angiogenic drug Avastin, 
tremendous progress has been made in the field. Here we try to hypothesize ideas based on our 12 
 
findings  that  would  enhance  the  understanding  of  angiogenesis  manipulation  and  cancer 
progression both from a therapeutic and endogenous protein’s perspective.  
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Figure  1.  Steps  in  angiogenesis.  1)  Nutrient  deprived  tissue  produces  pro-angiogenic 
molecules which are 2) released. These molecules 3) bind to the endothelial cells receptors on 
the blood vessel, causing 4, 5) an activation of cell proliferation. The presence of extracellular 
matrix molecules directs 6) the migration of cells by 7) remodeling. 8) Next, tube formation is 
followed by 9) loop formation and lastly 10) the blood vessel is stabilized by the stabilizing 
molecules present in the extracellular matrix.  
The Angiogenesis Process: How Do New Blood Vessels Grow? Copyright © 2009 by The 
Angiogenesis Foundation. All Rights Reserved. 14 
 
 
 
Figure 2. Activation of Notch signaling. Delta/Jagged from the signal sending cell interacts 
with the notch receptor from receiving cell. The binding causes a series of cleavages. First by 
metalloprotease tumor necrosis factor-α-converting enzyme (TACE), followed by proteins 
from ADAM family, and, last cleavage by Υ-secretase. This Υ-secretase cleaves the notch 
intra-cellular  domain  (NICD)  which  travels  to  the  nucleus  and  activates  the  suppressed 
RBPJk domain. This activated RBPJk causes the activation of transcription of Hes, which is a 
notch target gene.  
 15 
 
   
 
Figure 3. Cyclosporine-A’s mechanism of action. This involves binding of CsA to another 
protein  cyclophilin  (CpN);  this  combination  blocks  calcineurin.  Calcineurin  (CaN)  is 
important in the activation of interleukin-2 (IL-2) and T-cell proliferation. Nuclear factor of 
Activating T-cells (NF-AT) does not get dephosphorylated when CaN is blocked, therefore 
preventing Interleukin-2 transcription. FK506 is also shown to block CaN by binding FKBP, 
similar to CsA binding CpN.           Indicates activation;           I indicates inhibition.  
 16 
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Figure  4.  A  schematic  of  notch  ligands  interactions  and  cross-talk  with  CsA.  This  figure 
outlines a schematic we hypothesized and tested. Figure illustrates the pro vs. anti-angiogenic 
activities  that  are  modulated  by  notch  signaling  ligands.  Jag1  drives  angiogenesis  by 
promoting VEGF, which is well-established as a pro-angiogenic molecule. Addtionally dll4 
blocks  the  action  of  Jag1,  maintaining  a  balanced  angiogenesis.  We  hypothesize  that 
cyclosporine + cyclophilin inhibits the Jag1 driven activity similar to its inhibition of immune 
response.  17 
 
 
 
 
CHAPTER 2 
 
INHIBITION OF LUMEN FORMATION BY CYCLOSPORINE-A THROUGH NOTCH 
PATHWAY 
 
Abstract 
Clinical inhibition of angiogenesis is a promising approach to cancer treatment yet the 
efficacy of existing anti-angiogenic drugs has proven to be limited.  Additional methodologies 
must be explored in order to find alternative anti-angiogenic approaches to cancer patient care.  
Cyclosporine A (CSA) is a commonly used immunosuppressant that functions by blocking the 
cyclophilin A and calcineurin/NFAT signaling pathways.  In addition, it has been known for 
some time that CSA also blocks angiogenesis; however the mechanistic basis for this activity is 
poorly  understood.    To  examine  the  effect  of  CSA  on  angiogenesis,  we  treated  transgenic 
Fli1/Gata1 zebrafish embryos with CSA and monitored vascular development of function over a 
period of four days.   CSA did not affect the initial development of vascular structures including 
the  sprouting  of  intersegmental  vessels  from  the  dorsal  aorta.    However,  after  2  days,  CSA 
treated fish exhibited a pronounced absence of blood flow that was caused by the progressive 
loss of vascular luminal structures.  Phenotypically, the loss of vascular lumen structure was 
similar to the effect of notch inhibition and we therefore examined the effect of CSA on notch 
signaling.  CSA suppressed notch mediated transcriptional activity as judged by luciferase assay 
in transfected cells and by GFP fluorescence in Tp1bglob:eGFP transgenic fish.  Interestingly, 18 
 
CSA selectively suppressed jagged1 but not dll4 mediated notch activation.  Finally, selective 
inhibition  of  either  cyclophilin  A  with  N-MeVal-4-CsA  or  calcineurin/NFAT  with  FK506 
independently  resulted  in  loss  of  vascular  lumens  suggesting  these  pathways  function 
synergistically to promote vascular lumen malignance.  Collectively, these results provide insight 
into the mechanistic basis by which cyclosporine affects vascular function. 
Introduction  
The therapeutic inhibition of tumor angiogenesis remains a promising but elusive target.  
Existing technologies and drugs have failed to show significant long-term benefits.  Moreover, 
the cost of drug research and development has caused many existing anti-angiogenic drugs to be 
prohibitively expensive.  Therefore, the identification of low cost alternatives for anti-angiogenic 
therapy is a priority for current angiogenesis researchers. 
  Cyclosporine-A  (CsA)  is  a  known  immunosuppressant  that  functions  by  forming  a 
complex  with  cyclophilin  A  [61].    The  cyclophilin-A  –  CSA  complex  in  turn  binds  to  and 
suppresses the phosphatase calcineurin which is required for NFAT dephosphorylation to drive 
cytokine transcription.  In addition to immunosuppresson, CSA has also been shown to possess 
anti-angiogenic  activity.    In  particular,  CSA  suppress  angiogenesis  in  a  variety  of  models 
including the chick CAM [62, 63], rat mesenteric-window [64], in transplanted pancreatic islets 
[65], and finally in cultured HUVEC endothelial cells cultured on Matrigel [44].  Despite these 
reports, the molecular  mechanism by  which CSA suppresses angiogenesis is poorly defined.  
However,  it  is  likely  the  anti-angiogenic  activity  of  CSA  is  mediated  by  inhibition  of  the 
cyclophilin  A  –  Calcineurin/NFAT  signaling  pathway.    In  support  of  this,  the  calcineurin 
inhibitor FK506 has been shown to suppress angiogenesis [66, 67] suggesting that CSA blocks 19 
 
angiogenesis by indirectly blocking calcineurin activity via cyclophilin A binding.  Contrary to 
this idea however, direct inhibition of cyclophilin A also regulates angiogenesis [68].  Moreover, 
the  non-immunosuppressive  analog  of  CSA  (N-MeVal-4-CsA)  does  not  block  calcineurin 
activity  but  maintains  anti-angiogenic  activity  suggesting  that  cyclophilin  A  rather  than 
NFAT/calcineurin is linked to angiogenesis [44].  Therefore, significant controversy still exists 
about how CSA manipulates angiogenesis. 
  In  addition  to  the  cyclophilin  A  –  NFAT/calcineurin  signaling  cascade,  additional 
evidence also suggests that CSA may interact with the notch signaling pathway.  For example, in 
endothelial cells treated with CSA, the notch responsive HESR1 gene was increased more than 
any other analyzed gene [69].  Interestingly, Mammucari et. al. have discovered that integration 
of the notch and NFAT/calcineurin signaling pathways seems to be important for keratinocyte 
differentiation  [49].    Similarly,  Zanotti  et  al  have  identified  notch  and  NFAT  signaling  as 
reciprocally inhibiting pathways that together regulate osteoblast function [70].  
  Notch signaling has emerged as a major regulator of angiogenesis [71].  In particular, two 
notch ligands, Jagged1 and Dll-4 are described as having opposing impacts on angiogenesis.  
Jagged-1 promotes angiogenesis by stimulation of VEGF signaling and the endothelial tip cell 
phenotype,  while  Dll-4  suppresses  angiogenesis  by  promoting  the  stalk  cell  phenotype  and 
vascular  lumen  formation  [71].    Physiologically,  a  balance  between  the  opposing  forces  of 
Jagged1 and Dll-4 is critical for both the establishment and maintenance of a functional vascular 
system.  Based on the importance of notch signaling in angiogenesis, new therapeutic approaches 
have focused on disruption of notch signaling as a means to control angiogenesis [72]. 20 
 
  Herein,  we  expand  our  understanding  of  the  anti-angiogenic  activity  of  CSA.  
Specifically, our results in zebrafish embryos suggest that CSA does not inhibit angiogenesis per 
se in, but rather causes a collapse of vascular lumens.  Moreover, our results show that inhibition 
of both the cyclophilin A and calcineurin/NFAT signaling pathways leads to vascular defects, 
however only cyclophilin-A impacts notch signaling. 
  Material and Methods 
Fish Model 
 Transgenic zebrafish (fli1:GFP/gata1:RFP) expressing green fluorescent protein (GFP) 
in endothelial cells and red fluorescent protein (RFP) in blood cells, donated by Stephen C. 
Ekker (Mayo Clinic, Rochester MN), used from the fish facility at Indiana State University and 
maintained under husbandry conditions. These transgenic zebrafish were used for blood flow 
study with CsA.  
Green/Red  fluorescent  fish  that  constitutively  express  GPF  or  RFP  respectively  were 
gifted by Stephen C. Ekker (Mayo Clinic, Rochester MN). These fish were maintained under 
husbandry  conditions  at  the  fish  facility  in  Indiana  State  University.  Effects  of  CsA  on 
constitutively active notch were tested.  
Cell culture   
Cells were grown at 37°C with 5% CO2 in humidified environment. Human mammary 
epithelial cells (HMEC) were cultured in EGM-2 media (Lonza Cologne GmbH). A simian virus 
40-transformed mouse endothelial cell line (SVEC) was cultured in DMEM media with 10% 
fetal bovine serum (FBS).  21 
 
  Western blot:  400,000cells/well were cultured in a 6 well plate and transfected with 2μg 
DNA of notch1 and jagged1. 24 hours post transfection the cells were treated with CsA and 
FK506  and  incubated  for  24  hours.  The  following  day  media  was  aspirated  and  cells  were 
collected and run on 10% SDS-PAGE gel. The primary antibody used was cleaved notch (Val-
1744) (Cell signaling technology, Beverley, MA)(1:500 dilution). The bound primary antibody 
was detected by horseradish peroxidase-conjugated anti-mouse-Ig secondary antibody (1:2000) 
(GE healthcare, UK). Membrane was used for analysis and levels of notch were recorded (figure 
4A).  
Luciferase reporter gene assay  
Hes-1 activation levels were measured by luciferase levels. HMEC cells were cultured in 
a 24 well plate at density of 20,000 cells/ well and allowed to adhere overnight. These cells were 
transfected with LT-1 liposome (Mirius, Madison, WI) with 300 ng/well of notch1and delta4. In 
addition 100ng/well CMV-ß-gal was added to each well as a control of transfection efficiency. 
24 hours post transfection media was aspirated and cells were washed twice with PBS, the media 
was replaced with Serum free media (SFM) +/- CsA and cells were incubated overnight. On the 
following day, these cells were aspirated and luciferase levels were measured, in Glomax 96-
microplate-luminometer  (Promega,  USA),  using  Hes-1  luciferase  reagent  (Promega,  USA). 
These values were normalized for transfection using Beta-Glow reagent (Promega, USA).  
GFP levels in Notch fish 
 Transgenic fish (Tp1bglob:eGFP) expressing notch responsive reporter in the endothelial 
cells were donated by Dr. Steven D. Leach of John Hopkins University School of Medicine, 
Baltimore, MD. These fish express GFP endogenously and the effect of CsA at 10μM on the 22 
 
notch  expression  was  measured  using  a  cytoflour™  II  fluorescence  multi-well  plate  reader 
(PerSeptive Biosystems) at 530nm emission wavelength.  
Statistical analysis 
Standard  statistical  analysis  was  performed  in  all  experiments.  Student’s  t-test  was 
performed when determining the p-values for significance.  
  Results 
Cyclosporine disrupts vascular lumens in zebrafish embryos. 
  The  common  immunosuppressant  cyclosporine  A  has  been  shown  to  suppress 
angiogenesis in several experimental models including mice, transplanted pancreatic islets, and 
the chicken cam assay [62, 64, 65].  In recent years, zebrafish has emerged as a premier model in 
which  to  examine  several  physiological  processes  including  angiogenesis.    In  particular,  the 
development of zebrafish lines expressing GFP from the endothelial specific Fli-1 promoter and 
RFP  expression  from  the  blood  cell  specific  GATA-1  promoter  have  provided  a  unique 
perspective  on  angiogenesis.    Therefore,  we  set  out  to  investigate  whether  CSA  would  also 
impact angiogenesis in Fli-1 GFP/ GATA-1 RFP zebrafish and if new information could be 
discovered about the mechanism by which CSA inhibit angiogenesis.  Freshly laid zebrafish 
embryos were incubated in solutions of either 10µM CSA or an equivalent dilution of drug 
vehicle (DMSO, 1:100 dilution).  In both control embryos and embryos treated with CSA for 24 
hours, development of the aorta and cardinal vein was normal (data not shown).  Contrary to the 
reported anti-angiogenic activity of CSA, however, initial sprouting of intersegmental vessels 
from the aorta, and later the anastomosis of ISV vessels to form the dorsal lateral anastomotic 
vessel (DLAV) were also unaffected by CSA treatment (Figure 1A).  This observation suggested 23 
 
that early angiogenic activities are not affected by CSA.  Finally, early cardiac development and 
function was not obviously impacted by CSA since cardiac contractions and blood flow in both 
control and CSA treated fish began approximately 48 hours after fertilization (data not shown). 
The fact that cardiac contractions and blood flow began at essentially the same time in control 
and CSA treated embryos is important since the establishment of blood flow and hemodynamics 
has been shown to be important for the development a branching vascular network.  The most 
striking  impact  of  CSA  on  vascular  development  was  that  100%  of  the  CSA  treated  fish 
eventually experienced a complete loss of blood flow through ISV vessels and later through 
aortas that was associated with pooling of blood in the common cardinal vein (Fig 1B).  High 
power  imaging  of  ISV  vessels  in  CSA  treated  fish  revealed  a  progressive  loss  of  luminal 
structure in ISV vessels and aortas (Figure 1C).  Interestingly, the loss of luminal structure was 
not obviously related to heart malfunction since cardiac contractions in CSA treated zebrafish 
proceeded normally even after blood vessel occlusion was observed.  By 4 days post fertilization, 
luminal structures in CSA treated zebrafish had collapsed entirely  and blood flow was non-
existent (Figure 1D). 
Global Notch suppression partially rescues vascular flow and lumen maintenance 
  The loss of luminal structures within the ISV vessels of CSA treated embryos was both 
phenotypically and temporally similar to the effect of Delta-like 4 knockdown on ISV vessels.  
In particular, morpholino based knockdown of Dll-4 does not cause an initial defect in  ISV 
formation  but  rather,  Dll-4  morphants  experience  an  abnormal  persistence  of  angiogenic 
sprouting  that  is  accompanied  by  loss  of  ISV  luminal  structure  [73].    The  effect  of  Dll-4 
knockdown on vascular development and function has been attributed to a disruption of the 
balance  between  pro-angiogenic  Jagged-1  and  anti-angiogenic  Dll-4  signaling.    Therefore 24 
 
although  we  did  not  observe  the  persistence  of  angiogenic  sprouting  observed  after  Dll-4 
knockdown, we nonetheless hypothesized that CSA treatment somehow disrupted the balance 
between Dll-4 and Jag1 leading to lumen collapse.  We rationalized that application of a wide 
spectrum  inhibitor  of  notch  signaling  might  simultaneously  block  both  dll4  and  jag1  to  re-
establish a rebalanced, albeit reduced activity of notch signaling, and rescue luminal collapse and 
blood flow.  To test this hypothesis, we treated freshly laid zebrafish embryos with either 10µM 
CSA, 15µM DAPT, or a combination of CSA and DAPT.  As shown in figure 2, CSA again 
disrupted luminal formation while DAPT did not appear to have any noticeable effect on either 
vascular network development nor on blood flow.  Importantly however, simultaneous treatment 
with both CSA and DAPT elicited a rescue of flow dynamics in ISV and aortic vessels.  This 
rescue was not permanent however since eventually even fish treated with both CSA and DAPT 
experienced vascular occlusion.  Interestingly, co-treatment with CSA and DAPT also elicited a 
striking curvature of the developing embryos further suggesting cooperation between CSA and 
notch signaling. 
CSA suppresses Notch signaling 
  DAPT suppressed the CSA induced loss of vascular lumens and blood flow through ISV 
and aortas suggesting that CSA somehow impacted notch signaling in the endothelium of ISV 
vessels.    To  specifically  test  if  CSA  regulates  notch  signaling  we  used  a  Hes-1  luciferase 
construct to examine transcriptional activity from the notch sensitive Hes-1 promoter.  The Hes-1 
luciferase reporter was transfected into HMEC endothelial cells that were subsequently treated 
with 10µM CSA or DMSO control.  As shown in figure 3A, luciferase activity was significantly 
reduced in CSA treated cells.  To further examine the effect of CSA on notch signaling, we 
monitored the effect of CSA on notch activity in transgenic zebrafish expressing GFP from the 25 
 
notch responsive TP1 element (i.e. Tp1bglob:eGFP) as previously described [74].  Freshly laid 
Zebrafish embryos were incubated in either 10µM CSA, an equivalent volume of DMSO, or 
10µM DAPT as a positive control for reduced notch signaling.  After 24 hours, GFP expression 
in  the  control  and  treated  embryos  was  compared  by  measuring  GFP  fluorescence  in  the 
complete embryo.  As shown in figure 3B, both DAPT and CSA significantly decreased GFP 
fluorescence indicating that both drugs suppressed notch signaling. 
  Notch  activation  during  angiogenesis  is  critical  for  the  development  of  functional 
vasculature  and  emerging  research  shows  that  the  notch  ligands  jagged1  and  dll1  have 
independent  functions  during  angiogenesis.    Dll-4  is  required  for  suppression  of  tip  cell 
phenotypes and for malignance of lumenized vasculature while Jagged1 is required to promote 
tip cells and for initial establishment of vascular networks [71].  Morpholino mediated deletion 
of dll4 produces a phenotype that in some aspects is similar the effect of CSA on zebrafish 
embryos.  In particular, dll4 morphants exhibit no change in ISV sprouting and initially develop 
a vascular lumen that soon after development collapses and fails to support blood flow [73].  
Therefore,  based  on  this  similarity,  we  hypothesized  that  CSA  treatment  specifically  blocks 
activation of dll4-notch signaling in developing endothelium.  To test this hypothesis, we used 
western blots to compare jagged1 or dll-4 stimulated notch1 activation in the presence or absence 
of  CSA.   293T  cells  were  transiently  transfected  with  either  notch1  coda  alone,  notch1  and 
Jagged1 cDNAs, or notch1 and dll4 cDNAs then treated with 10µM CSA.  Notch activation was 
monitored  by  western  blot  analysis  with  antibodies  that  specifically  detected  the  epitope 
generated by cleavage of notch1 at Val1744 during the production of the active notch1 N1ICD 
fragment.  As shown in figure 3C, N1ICD cleavage was activated by both jagged1 and dll4; 26 
 
however, contrary to our hypothesis, dll4 – notch signaling was not affected while jagged1 – 
notch signaling was suppressed by CSA treatment.   
Cyclophilin A and NFAT/calcineurin are required for lumen stabilization 
  Binding of CSA to cyclophilin A forms a complex which in turn deactivates calcineurin 
and the NFAT phosphatase resulting in suppression of IL-2 transcription and T-cell activation 
[61].  Previous results show that signaling through the calcineurin/NFAT pathway is required for 
endothelial cells to respond to VEGF [75] suggesting that angiogenesis suppression by CSA is 
mediated by calcineurin/NFAT signaling.  Independently however, cyclophilin A has also been 
implicated in angiogenesis regulation since a CSA analog unable to suppress calcineurin/NFAT 
maintains anti-angiogenic activity [44] and cyclophilinA in isolation promotes angiogenesis [68].  
Based on these observations, it was important to determine whether CSA mediated inhibition of 
calcineurin/NFAT or cyclophilin A was responsible for the loss of vascular luminal structures 
observed  in  CSA  treated  zebrafish  embryos.    To  accomplish  this,  we  specifically  inhibited 
calcineurin/NFAT signaling using the immunosuppressant tacrolimis (FK506).  Treatment of 
zebrafish embryos with 2µM solutions of tacrolimus recapitulated the effect of CSA on vascular 
lumenization  (Fig  4).    To  determine  if  tacrolimus  also  blocked  notch  signaling  we  treated 
Tp1bglob:eGFP transgenic zebrafish with 2µM tacrolimus or DAPT.  As shown in figure 3B, 
tacrolimus did not affect GFP expression.  Moreover, 293T cells transfected with combinations 
of notch and jagged1 or dll-4 and subsequently treated with tacrolimus did not demonstrate any 
effect on notch activity as judged by western blot analysis with anti-N1ICD antibodies (Fig 3C).  
  To determine if CSA impacted luminal structures via cyclophilin A we utilized the CSA 
analog  N-MeVal-4-CsA  which  blocks  cyclophilin  A  activity  but  does  not  block 
calcineurin/NFAT signaling [44].  As shown in figure 5, N-MeVal-4-CsA also caused a loss of 27 
 
vascular  lumen  structures  although  4-fold  more  (i.e.  40  µM)  CSA  analog  was  required  to 
recapitulate the effect of CSA.  As opposed to tacrolimus, however, N-MeVal-4-CsA suppressed 
notch signaling in a manner identical to CSA.  As shown in figure 3C, CSA suppressed Jagged1 
mediated  N1ICD  processing  but  not  dll-4  mediated  N1ICD  processing.    Collectively,  these 
results suggested that both the calcineurin/NFAT and cyclophilin A pathways are required for 
proper  maintenance  of  vascular  lumen  structures  and  that  notch  signaling  is  regulated  by 
cyclophilin A but not NFAT/calcineurin signaling. 
  Discussion 
  Effective  cancer  therapy  by  anti-angiogenesis  approaches  continues  to  be  a  largely 
unsuccessful  endeavor.    While  the  existing  anti-angiogenic  drugs  have  proven  successful  in 
extending cancer patient life spans, these same drugs have failed to achieve the promise of anti-
angiogenic therapies for cancer treatment.  Therefore the development and characterization of 
additional  anti-angiogenic  agents  that  function  through  alternative  mechanisms  are  required.  
Cyclosporine A has been shown to suppress angiogenesis however the mechanistic basis for this 
has not been thoroughly investigated.   
To closely examine the effect of CSA on angiogenesis, we treated zebrafish embryos 
with  CSA  and  monitored  vascular  development  and  function  via  fluorescent  microscopy.  
Despite previous reports indicating that CSA is anti-angiogenic, our results show that CSA does 
not  impact  the  initial  development  of  angiogenic  sprouts,  but  rather  is  critical  for  the 
maintenance of vascular lumens.   
CSA is well known to form a complex with cyclophilin-A which, in turn, binds to and 
inactivates the phosphatase calcineurin.  In turn, calcineurin is unable to dephosphorylate NFAT 28 
 
which is required for NFAT mediated transcription of the IL-2 gene and T-cell activation [61].  
Thus, CSA blocks both cyclophilin A and calcineurin signaling pathways.  Interestingly, both 
cyclophilin A and calcineurin have been associated with angiogenesis.  Most recently, specific 
suppression of cyclophilin A was shown to suppress angiogenesis both in vitro and in vivo [44], 
although the mechanistic basis for this suppression has not been identified.  Likewise, FK506 
mediated suppression of NFAT results in decreased angiogenesis [67].  Our results coincide with 
these results since we find that specific and independent inhibition of cyclophilin A or NFAT 
both result in a loss of vascular lumen structures in zebrafish embryos. 
  Given that suppression of cyclosporine has been shown to inhibit VEGF, it is tempting to 
link CSA mediated vascular collapse to diminished VEGF signaling.  However, treatment of 
zebrafish embryos with specific VEGF inhibitors including SU5416 [76] or PTK787 [77] results 
in a dramatic loss of overall ISV development.  In contrast, we found that ISV vessels initially 
develop  normally  in  CSA  treated  fish  but  are  unable  to  maintain  vascular  lumen  structures.  
Therefore, suppression of VEGF alone is not consistent with our results and suggests that CSA 
stimulated lumen collapse involves alternative or additional signaling pathways.  In particular, 
the vascular collapse initiated by CSA is recapitulated by suppression of notch signaling via dll4 
deletion in zebrafish embryos [78] suggesting that CSA may destabilize vascular malignance by 
suppression  of  notch  signaling.    In  support  of  this,  we  determined  that  CSA  blocks  notch 
mediated  transcriptional  activity  and  notch  processing  in  transfected  cells  and  overall  notch 
signaling  in  zebrafish  embryos.  Moreover,  we  found  that  suppression  of  notch  is  linked  to 
cyclophilin A since the CSA analog N-MeVal-4-CsA suppressed notch activity while specific 
inactivation of NFAT with FK506 did not impact notch signaling.  Similarly, Shah et al reported 
that  CSA  mediated  angiogenesis  suppression  involves  transcriptional  control  of  the  notch 29 
 
responsive gene HesR1 and that FK506 is unable to impact HesR1 [69].  Collectively, these 
results  show  that  notch  activation  is  regulated  by  cyclophilin  A  but  not  calcineurin/NFAT 
signaling. 
  Notch control of vascular development and function involves a balance between pro-
angiogenic jagged1 signaling and anti-angiogenic dll4 signaling.  Specific suppression of dll4 is 
associated with loss of vascular structures as well as abnormal sprouting from quiescent blood 
vessels [60, 73] however specific inactivation of jagged1 has not been reported. Interestingly, we 
found  that  CSA  does  not  appear  to  indiscriminately  suppresses  notch  signaling  since  CSA 
suppressed jagged1 but not dll4 mediated notch activation.  We therefore hypothesized that CSA 
disrupts the balance between jagged1 and dll4 to suppress lumen maintenance.  In support of this 
hypothesis, treatment of DAPT which equally suppresses jagged1 and dll4 did not block vascular 
lumen structures alone but did partly rescue the blood flow in CSA treated embryos suggesting 
that co-suppression of dll4 and jagged1 restores a balance between these opposing forces on 
vascular function. 
Conclusion 
In  conclusion,  we  have  provided  evidence  that  CSA  suppresses  vascular  lumen 
maintenance in zebrafish embryos by suppression of both cyclophilin A and calcineurin/NFAT 
signaling  pathways.    Moreover,  we  have  identified  a  novel  activity  for  CSA  that  involves 
cyclophilin-A mediated suppression of notch signaling. We have hypothesized a schematic for 
the cross talking of the signaling mechanisms (Fig 6) and shown evidence for it. We believe 
these results will be important to future studies that seek to utilize CSA as an anti-angiogenic 
therapy for cancer treatment 30 
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Figure 1. CsA blocks blood flow in fish. Freshly laid eggs from transgenic fish expressing 
GFP in the vasculature along with RFP in the blood were treated with CsA A. shows fish 
24hpf. Treated with CsA these fish develop a normal vasculature. B. 48hpf the fish treated 
with CsA, even though develop normal vasculature, do not have blood flowing through 
them.  C.  96hpf  these  fish  looked  phenotypically  normal,  under  high  resolution  had  a 
collapsed lumen, in addition to no blood flowing through them. D. shows a quantification 
of blood flow in the fish. A significant number of fish with blocked blood flow in the 
vasculature were observed, when treated with CsA.   * p < .05. Abbreviation: hpf- hours 
post fertilization.  31 
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Figure 2: Reversal of flow by DAPT. A. shows the resuscitation of blood flow by DAPT. In 
addition  to  no  effects  on  lumen  formation  and  blood  flow,  DAPT  when  added  with  CsA 
(CsA+DAPT) reverse the blocked blood flow by CsA and prevent the collapsing of lumen. A 
‘crooked’ phenotype was observed with CsA+DAPT which indicated some cross-connection of 
the two drugs. B. shows a quantification of blood flow data. As shown DAPT not only had no 
effects on blood flow alone, reversed the inhibitory effects when added with CsA.  * p < .05. 
A. 
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Figure 3: Effects of CsA on Notch. A. Cyclosporine-A reduces Hes-1 levels in HMEC cells. 
HMEC cells were transfected with Hes-1 construct and treated with CsA and analyzed with 
luciferase analysis. A significantly lower notch activation is indicated by Hes-1 luciferase in 
cells  treated  with  CsA.  B.  Transgenic  (Tp1:eGFP)  fish  embryos  were  treated  with  CsA, 
DAPT, and FK506. CsA significantly lowered the notch activity but less than DAPT, while 
FK506 had no effects on notch levels. C. Shows effects of CsA on notch levels through a 
western  blot  analysis.  Transfected  cells  were  treated  with  CsA,  CsA-Analog  (Ana),  and 
FK506 (FK). Reduced notch levels were seen with CsA and CsA-Analog in notch1-jagged1 
while no effect was seen in notch1-delta4. FK506 did not lower the notch levels in either 
notch1-jagged1 or notch1-delta4.  
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Figure 4. Effects of FK506 on blood flow. Freshly laid Transgenic Fli1/Gata1 fish 
embryos  were  treated  with  FK506  and  examined  for  blood  flow  up  to  96hpf.  2µM 
FK506 caused the collapse of lumen and a no flow phenotype was observed. When 
observed under high resolution the lumens were collapsed and unlike the control no 
blood flow could be seen in the intersegmental vessels.   
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Figure  5.  Effects  of  N-MeVal-4-CsA  (CsA-Analog)  on  blood  flow.  Freshly  laid 
Transgenic Fli1/Gata1 fish embryos were treated with CsA-Analog and lumen formation 
and blood flow was examined up to 96hpf. Similar to CsA treated fish; CsA-Analog also 
caused a collapsed lumen phenotype and prevented the blood flow in the intersegmental 
vessels.   
  Control       CsA  CsA-Analog 
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Figure 6. Signaling mechanisms have a common target. We hypothesize that it is not 
either VEGF or  Notch that control  angiogenesis, but both mechanisms  have  a common 
target, angiogenesis. For instance, CsA+CpN is known to block calcineurin and also lower 
Notch levels, whereas FK506 blocks calcineurin and angiogenesis, but had no effects on 
Notch.  Also  CsA-analog,  which  does  not  block  calcineurin,  is  an  anti-angiogenic,  and 
angiogenesis is a common target for both calcineurin independent and dependent drug. The 
above schematic explains a possible mechanism that is supported by experimental data in 
chapter 2. 
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CHAPTER 3 
 
ROLE OF EXTRACELLULAR MATRIX MOLECULES LUMICAN AND MAGP2 IN 
ANGIOGENESIS AND CANCER PROGRESSION 
 
Introduction 
The importance of extracellular matrix (ECM) is well known due to the presence of ECM 
molecules that alter the development of new blood vessels required during tumorigenesis and 
angiogenesis [20, 21]. ECM, in addition to its structural components like collagens, also contains 
matricellular proteins, which are known to manipulate cell surface receptors. Additionally, ECM 
molecules can also control angiogenesis and thus tumor progression.  
This chapter deals into two parts, namely ‘role of matricellular protein Magp2 in angiogenesis’ 
and ‘role of matricellular protein Lumican in angiogenesis’.  
Role of Magp2 in angiogenesis  
Magp2 is known for its structural role in providing elastic stability to the blood vessels 
and tissues [31]. Presence of Magp2 in tumor microenvironment has been established in previous 
research  [20]  and  reveal  its  matricellular  role  in  the  tumor  microenvironment.  Moreover, 
previous researches have shown Magp2 to facilitate tumor progression and tumor cell survival 37 
 
[32] and its link to notch pathways have also been underlined [33], although its link to the notch 
developmental pathway has not been studied in much depth. Here we provide some preliminary 
data with Magp2 overexpressing tumor cells, which developed much faster than the control. 
These tumors not only developed at a higher rate but also possess a higher vasculature density. 
Studying  the  precise  mechanism  that  it  regulates  could  be  a  future  project,  built  on  the 
background data available here. 
Material and Methods  
The full length murine Magp2 cDNA were produced previously in the laboratory and 
inserted to the Lewis Lung Carcinoma (LLC) cells as described previously [79]. These cells were 
selected with Neomycin and maintained in the facility. Magp2 expression was measured by TCA 
50% DOC and 0.1% protein collected from the media (free of serum). The presence of Magp2 
was confirmed by Ni-NTA Agarose (Qiagen, CA, USA) that was bound from the media.  
One million Magp2 overexpressing cells or control cells were injected sub-cutaneous on 
the scruff of 12 week old C57BL/6 mice (Jackson Laboratories, ME, USA). Mice were injected 
in triplicate and experiments were repeated three times. Tumors were measured every day for 
fifteen days post injection. Tumor volume was calculated by: Volume = (W
2 x L)/2; where W is 
the width of the tumor and L is the length. On the fifteenth day the mice were euthanized and 
tumors were removed and weighed. All procedures were performed in accordance to the animal 
protocol procedure by the Institutional Animal Care And Use Committee (IUCAC) of Indiana 
State University.  
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Immunohistochemistry 
Immunohistochemistry  for  vascular  density  was  performed  to  measure  the  vascular 
density in the Magp2 overexpressing tumors.  Tumors were fixed in paraformaldehyde (4%) for 
an hour, followed by 70% ethanol. Tumors were then sectioned and stained with anti-mouse 
CD31 staining (Clarian Pathology Laboratory, Indiana University Indianapolis IN) which stains 
for  blood  vessels.  Vascular  density  was  calculated  by  measuring  the  vascular  staining  and 
compared between the control and Magp2 overexpressing tumors.  
Results  
Magp2 overexpressing cells showed a higher rate of tumor development as shown in 
figure 1. Tumor size was measured for a period of fifteen days, upon reaching a volume of 1cm
2.  
On the last day the mice were sacrificed and the tumors were dissected out, weighed and volume 
was  recorded.  Tumor  sections  were  stained  with  CD31  to  measure  vascular  density  and  a 
significantly increased level of vascular density was seen. Figure 1 shows quantified analysis of 
the tumor growth over a period of fifteen days. Vascular density analysis by CD31 staining 
revealed a significantly increased vessel density in Magp2 overexpressing tumors. These results 
showed  a  very  strong  correlation  of  Magp2  overexpression  and  angiogenesis.  While  tumors 
developed faster than normal, a higher vascular density indicated a higher rate of angiogenesis. 
This  data  were  consistent  with  the  previously  shown  data  [80]  where  an  increased  rate  of 
angiogenesis was shown with Magp2 via notch pathway.   
Role of Lumican in angiogenesis  
For decades, prostate cancer has been the most prevalent form of non-skin cancer among 
men in United States. According to the National Cancer Institute an estimated 241,740 new cases 39 
 
of prostate cancer will be diagnosed in year 2012, while almost 30,000 people will die from 
cancer. The rate of prostate cancer differs among races as well as geographical conditions. For 
example men of African American race in United States had a higher rate than African men. 
Similarly a lower rate of prostate cancer was recorded for indigenous Japanese men but was 
more than tripled for the same race born in the United States [81]. What is the cause of higher 
risk of prostate cancer among men in developed nations? What are the developments in our fight 
against cancer? There has been good news over the years due to the remarkable research in the 
field of cancer both in United States and worldwide. The 10-year survival rate for prostate cancer 
was 87%, while over half of the patients showed a progression free 10 years when treated for the 
disease  [82].    The  first  approach  of  treatment  against  prostate  cancer  today  is  androgen 
withdrawal but cases of androgen independent resurgence of prostate cancer are also known [83]. 
Therefore  a  need  to  investigate  androgen  independent  prostate  cancer  draws  attention  to 
extracellular matrix for its role in cancer proliferation.   
Role of ECM molecules has been established in cancer progression and proliferation. But 
there is an inconsistency with regards to the role of lumican in tumor microenvironment. It is 
shown to be increased in certain cancer types while others had an opposite observation [22-25, 
27, 84]. Our previous research has shown reduced levels of lumican in murine fibrosarcoma and 
pancreatic adenocarcinoma tumors in mice, along with a significant decrease in the vasculature 
[20].  In  another  study  in  the  lab  (manuscript  unpublished)  reduced  levels  of  lumican  were 
reported in prostate cancer mice. Therefore we believed that presence or absence of lumican may 
be a determinant in androgen independent prostate cancer. This study was designed to determine 
the  extent  of  change  that  the  presence/absence  of  lumican  has  on  rate  prostate  cancer 
proliferation.   40 
 
Although  this  was  a  long  term  project,  and  more  research  will  be  required  before 
obtaining any significant results, this project was initiated by crossing two different transgenic 
mouse. These mice were selected for different genotype for future analysis.  
Material and Methods  
Transgenic mice called transgenic adenocarcinoma of mouse prostate (TRAMP) mice 
were purchased from The Jackson laboratory, Maine USA. These mice (C57BL/6-Tg (TRAMP) 
8247Ng/J) develop prostate cancer and metastatic tumors around the onset of puberty (about 20 
weeks of age).  
Another mouse model used for the lumican study was lumican knock-out mice. These 
mice have the lumican gene deleted (Jackson laboratory, Maine, USA). These mice have been 
maintained  in  the  mouse  facility  at  Indiana  State  University. All  studies  were  performed  in 
accordance to the Institutional Animal Care And Use Committee at Indiana State University.   
Mice heterozygous for lumican (+/-) were crossed with mice heterozygous for TRAMP 
(+/-). First generation was genotype and selected for Tramp (+/-) Lumican(+/-) in an individual 
mouse. These mice will be crossed with other Tramp (+/-) Lumican (+/-) and selected for Tramp 
(+/-) Lumican(-/-) and Tramp (+/-) Lumican (+/+).  
Genotyping for lumican and TRAMP gene was done using RT-PCR. A 0.2 cm diameter
 
of mouse ear was clipped using clear sterile scissors. This was then mixed with 150µl DirectPCR 
Lysis Reagent (Ear) (Viagen Biotech, Inc. Los Angeles, California, USA). To this 0.2 mg/ml of 
Proteinase K (Sigma-Aldrich, St. Louis, Missouri, USA) was added. Ear specimen was then 
mixed in this solution at 55
oC overnight. This lysate was then incubated at 85
0 C for 45 minutes. 41 
 
Lysate was then centrifuged and stored at -20
0 C for future use. This crude lysate from mouse ear 
was used in PCR amplification and genotyping.  
Mouse ß- casein, size 500bp (forward: 5’-GATGTCCTCCAGGCTAAAGTT-3’; reverse: 
5’-AGAAACGGAATGTTGTGGAGT-3’)   was  used  as  control.  For  TRAMP  genotyping 
(forward: 5’-GCGCTGCTGACTTTCTAAACATAAG-3’; reverse: GAGCTCACGTTAAGTTTT 
GATGTGT) oligo, size 600bp, were generated (Jackson laboratory, Maine, USA). An optimizing 
temperature of 50
0 C was used for annealing.  PCR amplification was performed with 35 cycles 
(94
0 C for 30 sec, 50
0 C for 30 sec, 72
0 C for 45 sec). A BIORAD My Cycler ™ thermocycler 
(Bio-Rad laboratories, CA, USA) was used to optimize the PCR setting using above mentioned 
primers, 10X Standard Taq Reaction Buffer,  Taq DNA Polymerase, dNTP (New England Bio 
Labs, MA, USA). All  reactions were carried out at the final volume  of 25µl. This RT-PCR 
product was separated on a 15% polyacrylamide gel by electrophoresis for 20 minutes and DNA 
bands were observed under ultra-violet lamp (figure 2).  
Results    
First generation of crossing was successfully done with the two transgenic mice crosses. 
Genotyping results revealed the genetic makeup of the F1 generation. Presence of Lumican and 
TRAMP  gene  is  shown  in  figure  2  (as  a  double  band  lane  on  the  gel;  while  single  band 
represents wild type control mice or the absence of TRAMP gene). Lumican (+/-) TRAMP (+/-) 
mice were crossed for all possible genotypes. This project would deliver a very powerful tool to 
study the onset and progression of prostate cancer. These presence and absence of lumican was 
anticipated to have some effects on the proliferation of prostate cancer [20]. Although it requires 
more work to achieve the desired transgenic mouse for the study, once achieved this would 42 
 
answer many valuable questions about the effects of lumican on prostate cancer progression and 
angiogenesis. 
Conclusion 
With an increased knowledge of structural and matricellular proteins in the ECM, more 
findings are emerging in the field of cancer that proves this connection. Androgen independent 
prostate cancer has been linked to these proteins and their role in tumor microenvironment.  
We  show  an  increased  vascular  density  and  tumor  development  with  Magp2 
overexpression. Although much work is needed in this project to conclude concrete findings, it 
can provide a very good building ground for future research. Magp2 data was very significant 
and  Magp2  overexpressing  cells  showed  a  much  higher  rate  of  tumor  development,  with 
significantly higher vascular density (higher angiogenesis). 
Lower levels of lumican were previously shown in prostate cancer.  Here we attempt to 
cross  the  lumican  gene  into  TRAMP  mouse.  After  crossing  with  lumican  and  TRAMP,  a 
TRAMP positive/Lumican negative mouse should be achieved which would be a key point of 
analysis. 
Once TRAMP positive/Lumican negative mouse reaches puberty (around 12 weeks), the 
onset of prostate cancer would be triggered and can be tracked over a period of time.  
Much work is still required in this project to link the role of two proteins ‘Magp2’ and 
‘Lumican’ to angiogenesis and cancer progression. In conclusion, this project provides a good 
foundational work for future experiments.  43 
 
 
   
Figure 1. Tumors overexpressing Magp2 develop at a faster rate. 10
6 cells were injected 
subcutaneously in the mice and development of tumor was tracked over a period of fifteen 
days. A. shows the rate of development of Magp2 overexpressing tumors compared to the 
control. B. shows a real size picture of tumors. C. shows a CD31 staining of tumor cross-
section. An increased vasculature was seen in Magp2 overexpressing tumors.  
A. 
B. 
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   C            w/t          C(+/-)     w/t          T(+/-)   T(+/-) 
TRAMP￿ 
Control ￿ 
Lumican￿ 
Control ￿ 
Figure 2: Genotype results for Lumican and TRAMP. ‘2A’ shows results of genotyping 
on F1 generation for the TRAMP gene, while 2B shows mice genotyped for the Lumican 
gene. Presence of the control gene implies wild type (control) mouse, while presence of 
the lumican gene and control implies a heterozygous mouse. Abbreviations C: control, L: 
lumican, T: TRAMP, w/t: wild-type, (+/): Heterozygous. An endogenous ß-casein was 
used  as  control,  whereas  presence  of  TRAMP  gene  along  with  ß-casein  indicated 
TRAMP heterozygous. A RT-PCR protocol was used using primers for genes, standard 
Taq buffer, Taq DNA polymerase, and dNTP with an annealing temperature of 50
0 C. All 
products were separated on a 15% polyacrylamide gel by electrophoresis and observed 
under UV-lamp.  
+C      C      L(+/-)L(+/-)       L(+/-) w/t          L(+/-) 
A 
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